• Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • Home
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu

Captare. Aestimare. Eligere. Succedere.

CAPTIS – Your Global Healthcare & MedTech Executive Search Provider

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

GET HEADHUNTED!

Create and/or update

your confidential profile

 

Healthcare Executive General Information
Create an account & Add your profile

Go to our Careers page

 

 

 

 

 

CAPTIS Careers

Recent Healthcare News:

06/20/2019/by CAPTIS

RIBOMIC announces positive top-line results from phase 1/2a trial of rbm-007 in wet AMD

SUSHI study achieved the primary endpoint of safety and tolerability,…
06/20/2019/by CAPTIS

Ironwood and Allergan’s linaclotide succeeds in phase 3b trial in IBS-C

06/20/2019/by CAPTIS

Gamida Cell, Lonza establish commercial manufacturing agreement for omidubicel

06/20/2019/by CAPTIS

Gilead, Nurix collaborate to develop novel treatments for cancer and other diseases

06/19/2019/by CAPTIS

Rocket begins patient dosing in phase 1 trial of RP-A501 in Danon disease

06/19/2019/by CAPTIS

Novo Nordisk’s Victoza secures FDA paediatric approval for type 2 diabetes

06/19/2019/by CAPTIS

AstraZeneca, Merck get EC nod for Lynparza to treat advanced ovarian cancer

06/19/2019/by CAPTIS

Roche gets Japanese approval for personalised medicine Rozlytrek

06/18/2019/by CAPTIS

Mycovia, Jiangsu Hengrui to develop and commercialize antifungal therapy VT-1161

06/18/2019/by CAPTIS

Boehringer, OSE doses first patient in phase 1 trial of SIRPα antagonist monoclonal antibody

06/18/2019/by CAPTIS

Janssen’s guselkumab succeeds in phase 3 psoriatic arthritis trials

Guselkumab, which was subcutaneously injected in the participating…
06/18/2019/by CAPTIS

Pfizer to buy Array BioPharma for £9.06bn

06/17/2019/by CAPTIS

Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

06/17/2019/by CAPTIS

Dr. Reddy’s to sell neurology branded products to Upsher-Smith Laboratories

06/17/2019/by CAPTIS

AstraZeneca’s Lokelma shows significant effect in ESRD trial

06/14/2019/by CAPTIS

IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity

06/14/2019/by CAPTIS

Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab

06/13/2019/by CAPTIS

FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

06/13/2019/by CAPTIS

Pfizer announces results from XELJANZ XR ORAL Shift study

06/13/2019/by CAPTIS

Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

We Suggest:

Dassault Systèmes to buy Medidata Solutions for £4.5bn

0 Comments
/
06/13/2019
The acquisition of Medidata will help Dassault to create its…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-13 00:01:442019-06-13 00:01:46Dassault Systèmes to buy Medidata Solutions for £4.5bn

FDA extends approval of Merck’s Keytruda in head and neck cancer

0 Comments
/
06/12/2019
The regulator has approved Keytruda as monotherapy and also in…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-12 05:31:592019-06-12 05:32:00FDA extends approval of Merck’s Keytruda in head and neck cancer

Boehringer Ingelheim, University of Dundee extend anti-cancer alliance

0 Comments
/
06/12/2019
This brings together the expertise of Professor Alessio Ciulli,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-12 03:31:052019-06-12 03:31:06Boehringer Ingelheim, University of Dundee extend anti-cancer alliance

Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

0 Comments
/
06/12/2019
Cosentyx is claimed to be the first and only fully-human biologic,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-12 01:01:162019-06-12 01:01:17Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years

0 Comments
/
06/12/2019
Having established their collaboration in the 1980s, this extension…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-12 00:31:002019-06-12 00:31:03Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years

Genentech secures FDA accelerated approval for Polivy, BR combo for DLBCL

0 Comments
/
06/11/2019
The accelerated approval for the Polivy, BR combination is for…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-11 05:31:222019-06-11 05:31:23Genentech secures FDA accelerated approval for Polivy, BR combo for DLBCL

Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in moderate to severe plaque psoriasis

0 Comments
/
06/11/2019
In the study, PPC-06 met both co-primary endpoints i.e. PASI-75…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-11 03:31:092019-06-11 03:31:10Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in moderate to severe plaque psoriasis

Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development

0 Comments
/
06/11/2019
The acquisitions are part of Aptar’s strategy to broaden…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-11 00:31:022019-06-11 00:31:05Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development

Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

0 Comments
/
06/11/2019
Tilos Therapeutics is involved in the development of therapeutics,…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-11 00:01:042019-06-11 00:01:06Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

Theramex signs exclusive licensing and supply rights deal with TherapeuticsMD

0 Comments
/
06/10/2019
As per the terms of the deal, Theramex will have exclusive commercialisation…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-10 05:31:202019-06-10 05:31:21Theramex signs exclusive licensing and supply rights deal with TherapeuticsMD

nference enters into R&D data science partnership with Janssen

0 Comments
/
06/10/2019
“We are thrilled to be advancing this strategic alliance…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-10 03:31:202019-06-10 03:31:21nference enters into R&D data science partnership with Janssen

ProtoKinetix achieves primary objective safety at midpoint of clinical trial

0 Comments
/
06/10/2019
All six patients were recruited and treated under this protocol.…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-10 01:01:212019-06-10 01:01:22ProtoKinetix achieves primary objective safety at midpoint of clinical trial

Acucela gets European orphan designation for emixustat to treat Stargardt disease

0 Comments
/
06/10/2019
In January 2017, Acucela had received orphan drug designation…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-10 00:41:072019-06-10 00:41:08Acucela gets European orphan designation for emixustat to treat Stargardt disease

Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

0 Comments
/
06/07/2019
The Calquence, obinutuzumab combination registered a statistically-significant…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-07 04:32:552019-06-07 04:32:57Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

Novartis presents first-of-its-kind histology data with iscalimab

0 Comments
/
06/07/2019
“Extending the life of transplanted kidneys would mean…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-07 00:30:592019-06-07 00:31:01Novartis presents first-of-its-kind histology data with iscalimab

Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

0 Comments
/
06/07/2019
Under the deal, Exonics equity holders will receive $245m (£192m)…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-07 00:01:472019-06-07 00:01:48Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease

0 Comments
/
06/06/2019
The Phase 1 study will evaluate the safety, tolerability, and…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 23:01:582019-06-06 23:02:00Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease

Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL

0 Comments
/
06/06/2019
The venetoclax, obinutuzumab combination met the primary endpoint…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 06:01:362019-06-06 06:01:37Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL

CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

0 Comments
/
06/06/2019
The trial is a multi-center, open-label, and multi-dose Phase…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 02:31:112019-06-06 02:31:15CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD

0 Comments
/
06/06/2019
ADPKD is the most common inherited form of kidney disease affecting…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 01:31:562019-06-06 01:31:57Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

News from Twitter

Twitter
BIO Intl Convention
BIO Intl Convention
@BIOConvention

Registration in the Grand Hall zipping right along at #BIO2019 this morning! We are looking forward to a great day of Partnering, education and networking. pic.twitter.com/e6Hb…

reply retweet favorite
11:12 am · 06/04/2019 ·
Retweeted by CAPTIS
Twitter
BIO Intl Convention
BIO Intl Convention
@BIOConvention

Good morning, Philadelphia! It's officially day 1 of #BIO2019-- here are today's highlights. View the full schedule of today's events in myBIO: bit.ly/2KfZcWp pic.twitter.com/w6uv…

reply retweet favorite
11:11 am · 06/04/2019 ·
Retweeted by CAPTIS
Twitter
Centinel Spine
Centinel Spine
@CentinelSpine

Congratulations to Rory Sabbatini, prodisc® athlete-ambassador, on his 6th place finish at the @CSChallengeFW. Rory and @BrianGayPGA played the green well this weekend—while educating @PGATOUR fans on spinal surgery with prodisc. bit.ly/2W9cUSb #regainyourlife

reply retweet favorite
9:47 pm · 05/28/2019 ·
Retweeted by CAPTIS
Twitter
TranS1
TranS1
@TranS1

I am lucky to work for a company that gives a person the ability to want to make every day count. TranS1 has given me the ability to stop looking back and remember how to live a life - Get back to living! #tuesdayteammember #T14life #lovewhereyouwork #lovewhatyoudo pic.twitter.com/IiCV…

reply retweet favorite
9:47 pm · 05/28/2019 ·
Retweeted by CAPTIS
Twitter
Quantum Genomics
Quantum Genomics
@QuantumGenomics

Nous profitons de la #JournéeMondialeContreLHypertension pour vous rappeler que notre mission est de développer de nouvelles thérapies innovantes pour les besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires. #Hypertension #Firibastat #QuantumGenomics pic.twitter.com/bELl…

reply retweet favorite
12:12 pm · 05/18/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Let's meet at #AAOS2019 in Las Vegas. Feel free to make contact. pic.twitter.com/Cybu…

reply retweet favorite
4:11 pm · 03/14/2019
Twitter
Dr. Alfredo Figueiredo
Dr. Alfredo Figueiredo
@AlfredoFig1

#LowBackPain - a good summary by the European Spine Society @EUROSPINESoc eurospinepatientline… #Orthopaedics #SpineSurgery pic.twitter.com/yo6E…

reply retweet favorite
5:05 am · 02/21/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Happy President's Day from CAPTIS!

reply retweet favorite
5:06 pm · 02/18/2019
Twitter
Medtronic Spine
Medtronic Spine
@Medtronic_Spine

We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…

reply retweet favorite
5:27 pm · 02/01/2019 ·
Retweeted by CAPTIS
Twitter
Arab Health
Arab Health
@Arab_Health

The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Q pic.twitter.com/oasI…

reply retweet favorite
5:35 pm · 01/29/2019 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine #ESMO18 pic.twitter.com/41QL…

reply retweet favorite
6:56 pm · 10/24/2018 ·
Retweeted by CAPTIS
Twitter
Epic CV
Epic CV
@Epic_CV

Read carefully employer's directions on how to apply. #resume #resumetips

reply retweet favorite
7:47 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
World Spine Care
World Spine Care
@WorldSpineCare

Here are 5 Tips to Avoid Back Pain from #WorldSpineDay. #Exercise #Posture #Stress #HealthyEating #Strength pic.twitter.com/AT1D…

reply retweet favorite
7:46 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Neurochecklists
Neurochecklists
@neurochecklists

Large-vessel giant cell arteritis: diagnosis, monitoring and management | Rheumatology | Oxford Academic academic.oup.com/rhe…

reply retweet favorite
7:40 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Stryker Endoscopy
Stryker Endoscopy
@StrykerEndo

Scientists have made an unexpected discovery while investigating the triggering factors of #ColonCancer: Cell stress in combination with an altered microbiota in the colon drives tumor growth. Learn more: ow.ly/JxtK30meLTY pic.twitter.com/U51Q…

reply retweet favorite
7:39 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Implantech
Implantech
@Implantech

If you are in Dallas attending the AAFPRS 12th International Symposium of Facial Plastic Surgery don’t miss out on this Breakfast Symposium tomorrow morning with Dr. William Binder that is sponsored by Implantech! #implantech #superiorpatientaesthetics #implantechrewards #aafprs pic.twitter.com/HCzK…

reply retweet favorite
7:38 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
American College of Cardiology
American College of Cardiology
@ACCinTouch

Less than one month left to submit your science for #ACC19! Abstract & case submissions are due Oct. 16. Learn more: ow.ly/4nyf30lYZxh pic.twitter.com/Mnwv…

reply retweet favorite
4:46 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStory pic.twitter.com/Xuoh…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Integra LifeSciences
Integra LifeSciences
@integra_life

Make plans to visit the Integra LifeSciences Booth# 919 during Plastic Surgery The Meeting September 28th - October 1st. #Integra_LifeSciences #DurableIsBeautiful #PSTM18 #ASPS #PlasticSurgery pic.twitter.com/8QGv…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Fundamental Surgery
Fundamental Surgery
@FundamentalSurg

We are live at #NASS2018 stand 2649. Get hands-on with the world's leading surgical #simulator in #VR with #haptics and experience the future of surgical training. #wearefundamental fundamentalsurgery.c… pic.twitter.com/NgzA…

reply retweet favorite
4:41 pm · 09/26/2018 ·
Retweeted by CAPTIS
Follow @CaptisCorp

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - copyright@captis.com
  • Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
X
Thank you for visiting our new website! Help us improve, let us know your feedback (Anonymous 2 min survey)
Survey
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top